Terapia innovativa: oltre il PEB? Relatore: Dr ... - Oncologia Rimini
Terapia innovativa: oltre il PEB? Relatore: Dr ... - Oncologia Rimini
Terapia innovativa: oltre il PEB? Relatore: Dr ... - Oncologia Rimini
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Prognostic factors in relapsed or refractory germ-cell tumors<br />
ASCO 2009 - Abstr # 5030<br />
A. Lorch, J. Beyer , C. Mollevi, M. Guerra, A. Kramar for the International Group on<br />
Prognostic Factors in Relapsed or Refractory Germ-Cell Tumors<br />
METHODS:<br />
Between 09/2007 and 12/2008 data on 1984 pts with rr-GCT were collected<br />
from 38 centers/groups worldwide (participating centers see below).<br />
Inclusion criteria were as follows<br />
> germ cell tumor defined either by histology and/or by markers<br />
> first-line chemotherapy after January 01,1990<br />
> at least three cycles of cisplatin-based first-line chemotherapy<br />
> unequivocal relapse or progression after first-line chemotherapy<br />
> no previous salvage chemotherapy<br />
> first-salvage chemotherapy with either conventional-dose<br />
cisplatin-based treatment or with any high-dose regimen
Change language